Hepatic Stress Associated with Pathologies Characterized by Disturbed Glucose Production
Overview
Affiliations
The liver is an organ with many facets, including a role in energy production and metabolic balance, detoxification and extraordinary capacity of regeneration. Hepatic glucose production plays a crucial role in the maintenance of normal glucose levels in the organism i.e. between 0.7 to 1.1 g/l. The loss of this function leads to a rare genetic metabolic disease named glycogen storage disease type I (GSDI), characterized by severe hypoglycemia during short fasts. On the contrary, type 2 diabetes is characterized by chronic hyperglycemia, partly due to an overproduction of glucose by the liver. Indeed, diabetes is characterized by increased uptake/production of glucose by hepatocytes, leading to the activation of lipogenesis and the development of a non-alcoholic fatty liver disease. In GSDI, the accumulation of glucose-6 phosphate, which cannot be hydrolyzed into glucose, leads to an increase of glycogen stores and the development of hepatic steatosis. Thus, in these pathologies, hepatocytes are subjected to cellular stress mainly induced by glucotoxicity and lipotoxicity. In this review, we have compared hepatic cellular stress induced in type 2 diabetes and GSDI, especially oxidative stress, autophagy deregulation, and ER-stress. In addition, both GSDI and diabetic patients are prone to the development of hepatocellular adenomas (HCA) that occur on a fatty liver in the absence of cirrhosis. These HCA can further acquire malignant traits and transform into hepatocellular carcinoma. This process of tumorigenesis highlights the importance of an optimal metabolic control in both GSDI and diabetic patients in order to prevent, or at least to restrain, tumorigenic activity during disturbed glucose metabolism pathologies.
Binayi F, Saeidi B, Farahani F, Sadat Izadi M, Eskandari F, Azarkish F Heliyon. 2024; 10(12):e32804.
PMID: 38975085 PMC: 11226834. DOI: 10.1016/j.heliyon.2024.e32804.
A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis.
Burelle C, Clapatiuc V, Deschenes S, Cuillerier A, De Loof M, Higgins M Commun Biol. 2024; 7(1):356.
PMID: 38519536 PMC: 10959946. DOI: 10.1038/s42003-024-06035-6.
H NMR Metabolomics on Pigs' Liver Exposed to Antibiotics Administration: An Explorative Study.
Fabrile M, Ghidini S, Caligiani A, Scali F, Varra M, Lolli V Foods. 2024; 12(23).
PMID: 38231703 PMC: 10706443. DOI: 10.3390/foods12234259.
Nonalcoholic Fatty Liver Disease-A Concise Review of Noninvasive Tests and Biomarkers.
Bassal T, Basheer M, Boulos M, Assy N Metabolites. 2022; 12(11).
PMID: 36355154 PMC: 9692389. DOI: 10.3390/metabo12111073.
Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice.
Franko A, Irmler M, Prehn C, Heinzmann S, Schmitt-Kopplin P, Adamski J Biomedicines. 2022; 10(3).
PMID: 35327418 PMC: 8945094. DOI: 10.3390/biomedicines10030616.